The mission of the Cell Therapies Core Facility (CTCF) is to produce the highest quality cellular products in support of novel, investigator-initiated clinical trials, and to facilitate the monitoring of immunologic function in cancer patients undergoing immune- and/or gene-based therapies. Cellular products that are administered to patients with therapeutic intent fall under the definition of Pharmaceuticals. The manufacture of these products is regulated by the Food and Drug Administration under the current Good Manufacturing Practices (cGMP) and current Good Tissue Practices (cGTP) statutes. The CTCF was designed, both physically and functionally to work within this regulatory framework, thus relieving the individual investigators of concern for this aspect of their research effort. To further facilitate translational research, the CTCF may be engaged throughout the process of developing clinical trials of novel cell therapy products. Specifically, the CTCF provides pre-clinical scale-up engineering for cell therapy products which have been developed in rodent models, and also handles all aspects of Investigative New Drug (IND) applications, from submission through initial approval. In addition the CTCF provides post-therapy immune monitoring performed on protocol in order to aid in the determination of the efficacy of specific cell and/or gene therapy agents in augmenting anti-neoplasia immunologic function. The CTCF occupies approximately 2700 sf containing five class 10,000 cleanrooms, two conventional labs for handling closed system products, a liquid nitrogen cell banking lab, an apheresis lab, and a cGMP/cGTP compliant materials storage area. All technologists are specifically trained in cGMP/cGTP production methods;all production is done under strictly documented processes;and, all activities, including personnel training, acquisition of materials and equipment, and production are scrupulously documented. A quality management plan under the coordination of a specific, independent individual is in place.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-11
Application #
7780400
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
11
Fiscal Year
2009
Total Cost
$97,971
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Persi, Erez; Duran-Frigola, Miquel; Damaghi, Mehdi et al. (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9:2997
Kim, Youngchul; Pierce, Christine M; Robinson, Lary A (2018) Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer 18:843
Chen, Yan; Zhu, Jin-Yi; Hong, Kwon Ho et al. (2018) Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem Biol 13:582-590
Rosenberger, Albert; Hung, Rayjean J; Christiani, David C et al. (2018) Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health 91:937-950
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75
Puri, Sonam; Hyland, Kelly A; Weiss, Kristine Crowe et al. (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26:2911-2918
Gonzalez, Brian D; Small, Brent J; Cases, Mallory G et al. (2018) Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer 124:499-506
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430

Showing the most recent 10 out of 1254 publications